Key points are not available for this paper at this time.
Artificial intelligence is being embedded in clinical trial infrastructure, shaping who is identified, stratified, and analysed. Opaque models risk amplifying existing disparities in the evidence base. We argue that embedded transparency, the structural integration of ex ante interpretability, demographic auditability, documented uncertainty handling, and stakeholder-relative explanation, is a necessary, though not sufficient, condition for equitable AI-enabled trials, and propose governance recommendations actionable across regulatory regimes.
Blom et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: